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Background
Previous animal studies showed that partial whey hydro-
lyates could prevent acute allergic symptoms in a mouse
model for cow’s milk allergy. This effect was even more
pronounced in combination with a diet containing a
specific non-digestible oligosaccharide mixture of sc-
Galacto- (scGOS), lc-Fructo- (lcFOS) and Acidic- (pAOS)
oligosaccharides (in a 9:1:2 ratio). We hypothesized that
these hydrolysates contain peptides that can induce the
observed tolerance. Therefore we investigated the poten-
tial of synthetic b-lactoglobulin peptides, with or without
a diet containing ScGOS/lsFOS/pAOS, to induce toler-
ance in this mouse model.
Methods
Female C3H/HeOuJ mice were treated for six consecutive
days with three synthetic b-lactoglobulin peptide mixes or
PBS. The peptides were selected based on human T cell
proliferation data and previous literature. During this
treatment period, mice were fed a control or sc GOS/
lcFOC/pAOS containing diet. Subsequently, mice were
sensitized five times with cholera toxin alone or in combi-
nation with whey and received an intradermal ear and oral
challenge 6 days later.
Results
Treating the mice with peptide mix 1 and 3 before sensiti-
zation reduced the acute allergic ear response. Peptide mix
2 showed no effect. The effect of peptide mix 1 was stron-
ger in combination with the scGOS/lcFOS/pAOS contain-
ing diet. No additional effects were observed for the other
mixes. Some mice showed reduced antibody responses but
no association with clinical responses was observed. Of
the peptides in mixture 1, one peptide showed the stron-
gest effect on the acute allergic skin response. This peptide
also tends to decrease whey-specific antibody levels and to
increase the percentages of CD11b+CD103+ dendritic
cells and CD25+Foxp3+ T cells in the MLN.
Conclusion
Pre-treatment with specific b-lactoglobulin peptides is able
to reduce the acute allergic response in a mouse model for
cow’s milk allergy suggesting that specific peptides are
capable of inducing tolerance which may involve regula-
tory dendritic and T cells. The tolerizing capacity could be
enhanced by the addition of a scGOS/lcFOS/pAOS con-
taining diet. Further research is necessary to determine
whether these peptides are present in the tolerance indu-
cing hydrolysates and the mechanism of action of these
peptides should be further investigated.
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